72 related articles for article (PubMed ID: 25383370)
1. Removal of endobronchial malignant mass by cryotherapy improved performance status to receive chemotherapy.
Fang YF; Hsieh MH; Wang TY; Lin HC; Yu CT; Chou CL; Lin SM; Kuo CH; Chung FT
ScientificWorldJournal; 2014; 2014():369739. PubMed ID: 25383370
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting survival in patients with endobronchial malignant mass after flexible Bronchoscopic cryotherapy: a cohort study.
Chung FT; Chou CL; Lo YL; Kuo CH; Wang TY; Wang CH; Huang HY; Lin HC; Chang CH; Lee CS; Chen HC; Lin SM
BMC Pulm Med; 2019 May; 19(1):101. PubMed ID: 31126271
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical benefits of the low dose rate endobronchial irradiation of malignant airway obstructions.
Spásová I; Petera J
Neoplasma; 2001; 48(3):234-40. PubMed ID: 11583295
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer.
Yuanying Y; Lizhi N; Feng M; Xiaohua W; Jianying Z; Fei Y; Feng J; Lihua H; Jibing C; Jialiang L; Kecheng X
Cryobiology; 2013 Oct; 67(2):235-40. PubMed ID: 23948179
[TBL] [Abstract][Full Text] [Related]
6. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids.
Daddi N; Schiavon M; Filosso PL; Cardillo G; Ambrogi MC; De Palma A; Luzzi L; Bandiera A; Casali C; Ruffato A; De Angelis V; Andriolo LG; Guerrera F; Carleo F; Davini F; Urbani M; Mattioli S; Morandi U; Zannini P; Gotti G; Loizzi M; Puma F; Mussi A; Ricci A; Oliaro A; Rea F;
Eur J Cardiothorac Surg; 2014 Apr; 45(4):677-86. PubMed ID: 24099733
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma.
Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kohno T; Shimizu C; Ando M; Kasamatsu T; Fujiwara Y
Oncol Rep; 2008 Feb; 19(2):497-503. PubMed ID: 18202800
[TBL] [Abstract][Full Text] [Related]
10. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications.
Micke P; Basrai M; Faldum A; Bittinger F; Rönnstrand L; Blaukat A; Beeh KM; Oesch F; Fischer B; Buhl R; Hengstler JG
Clin Cancer Res; 2003 Jan; 9(1):188-94. PubMed ID: 12538468
[TBL] [Abstract][Full Text] [Related]
11. Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer.
Kim HJ; Kim YJ; Seo MD; Yi HG; Lee SH; Lee SM; Kim DW; Yang SC; Lee CT; Lee JS; Kim YW; Heo DS
Lung Cancer; 2009 Aug; 65(2):242-6. PubMed ID: 19147252
[TBL] [Abstract][Full Text] [Related]
12. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
[TBL] [Abstract][Full Text] [Related]
13. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
[TBL] [Abstract][Full Text] [Related]
14. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.
Huang EH; Liao Z; Cox JD; Guerrero TM; Chang JY; Jeter M; Borghero Y; Wei X; Fossella F; Herbst RS; Blumenschein GR; Moran C; Allen PK; Komaki R
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):779-85. PubMed ID: 17418967
[TBL] [Abstract][Full Text] [Related]
15. Timely airway stenting improves survival in patients with malignant central airway obstruction.
Razi SS; Lebovics RS; Schwartz G; Sancheti M; Belsley S; Connery CP; Bhora FY
Ann Thorac Surg; 2010 Oct; 90(4):1088-93. PubMed ID: 20868793
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
[TBL] [Abstract][Full Text] [Related]
17. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
18. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
